Summary: For men between 50 and 69 years old with clinically localized prostate cancer detected by prostate-specific antigen (PSA) screening, active monitoring * appears to result in the same 10-year prostate-cancer-specific survival (~98%) and all-cause-mortality survival as either radiotherapy or prostatectomy.

 * – “Active monitoring” in this study consisted of frequent scheduled PSA levels, with a 50% increase in PSA value triggering clinical review and reassessment of management options; see full article for details.

Strength of Recommendation = B